Zobrazeno 1 - 10
of 164
pro vyhledávání: '"Phase IV Trial"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Snijders, R.J.A.L.M., Stoelinga, A.E.C., Gevers, T.J.G., Pape, S., Biewenga, M., Verdonk, R.C., Jonge, H.J.M. de, Vrolijk, J.M., Bakker, S.F., Vanwolleghem, T., Boer, Y.S. de, Pronk, M.A.M.C.B., Beuers, U.H.W., Meer, A.J. van der, Gerven, N.M.F. van, Sijtsma, M.G.M., Verwer, B.J., Gisbertz, I.A.M., Bartelink, M., Brand, F.F. van den, Korkmaz, K.S., Berg, A.P. van den, Guichelaar, M.M.J., Soufidi, K., Levens, A.D., Hoek, B. van, Drenth, J.P.H., Dutch Autoimmune Hepatitis Working
Publikováno v:
Trials, 23(1):1012. BioMed Central Ltd.
Trials, 23(1):1012. BioMed Central
TRIALS, 23(1):1012. BMC
on behalf of the Dutch Autoimmune Hepatitis Working Group 2022, ' Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial) : study protocol for a randomised controlled trial ', Trials, vol. 23, no. 1, 1012 . https://doi.org/10.1186/s13063-022-06890-w
Trials
Trials, 23(1). BMC
Trials, 23, 1
Trials, 23(1). BioMed Central Ltd
Trials, 23
Trials, 23(1):1012. BioMed Central
TRIALS, 23(1):1012. BMC
on behalf of the Dutch Autoimmune Hepatitis Working Group 2022, ' Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial) : study protocol for a randomised controlled trial ', Trials, vol. 23, no. 1, 1012 . https://doi.org/10.1186/s13063-022-06890-w
Trials
Trials, 23(1). BMC
Trials, 23, 1
Trials, 23(1). BioMed Central Ltd
Trials, 23
Background Currently, the standard therapy for autoimmune hepatitis (AIH) consists of a combination of prednisolone and azathioprine. However, 15% of patients are intolerant to azathioprine which necessitates cessation of azathioprine or changes in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f268f0c5f0c5d471147b4cc9c9b0876
https://hdl.handle.net/1887/3564045
https://hdl.handle.net/1887/3564045
Autor:
Ann D Bass, Joshua Katz, Edward Fox, Derrick Robertson, Danielle E. Harlow, Jacob A. Sloane, Brooke Hayward, Augusto Miravalle, Lori A Lebson
Publikováno v:
Neurodegenerative Disease Management. 11:99-111
Cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years) are approved for the treatment of relapsing forms of multiple sclerosis (MS), including relapsing-remitting MS and active secondary progressive MS. However, real-world data on cladribi
Autor:
Liangjun Zhu, Wei Wang, Jin Yan, Zuoxing Niu, Shujun Yang, Lu Wen, Zengqing Guo, Rui-Hua Xu, Feng Bi, Fenghua Wang, Yong Tang, Suzhan Zhang, Yanhong Deng, Bing Hu, Guanghai Dai, Min Tao
Publikováno v:
Chinese Journal of Cancer Research
Objective Bevacizumab has an important and evolving role in improving outcomes in patients with metastatic colorectal cancer (mCRC) worldwide and was approved in China in 2010. However, there are limited real-world data on the efficacy and safety of
Autor:
Leonard M. Fleck
Publikováno v:
Hastings Center Report. 51:9-11
Accelerated approval of aducanumab for mild Alzheimer's by the U.S. Food and Drug Administration on June 7, 2021, has generated substantial medical, scientific, and ethical controversy. That approval was contrary to the nearly unanimous judgment of t
Autor:
Paul Jennings, Carl Luckhoff, Lisa Brichko, Gerard O'Reilly, De Villiers Smit, Ravali Gaddam, Peter Cameron, Cristina Roman, Biswadev Mitra
Publikováno v:
Academic Emergency Medicine. 28:164-171
OBJECTIVE The objective was to evaluate the effectiveness of methoxyflurane versus standard care for the initial management of severe pain among adult emergency department (ED) patients. METHODS This randomized parallel-group open-label phase IV tria
Autor:
Christoph Riese, Rachel Wuerstlein, Hans Tesch, Nadia Harbeck, Johannes Schumacher, Ronald E. Kates, Christian Schem, Timo Schinköthe, Isabel Witzel, Christoph Thomssen, Sherko Kuemmel, Peter A. Fasching, Thomas Decker, Diana Lüftner, Tom Degenhardt, Marcus Schmidt, Volkmar Mueller, Christoph Uleer
Publikováno v:
Cancer Research. 80:OT3-14
Background: Efficacy and quality of life (QoL) are key factors when selecting therapies for metastatic breast cancer (MBC) patients. The addition of targeted oral agents such as CDK4/6 inhibitors to endocrine therapy is the new standard for hormone r
Autor:
Anita Amundsen, Oddbjørn Straume, Steinar Aamdal, Cornelia Schuster, Marta Nyakas, Christian Kersten, Astrid Dalhaug, Jarle Karlsen, Eva Skovlund, Kirsten T. Hagene, Jon Amund Kyte, Israr Hussain, Tormod Kyrre Guren, Kari Dolven Jacobsen, Stein Kaasa, Oluf Herlofsen, Kjersti Holmsen, Elin Aamdal, Hege G. Russnes
Publikováno v:
International Journal of Cancer
Ipilimumab was the first treatment that improved survival in advanced melanoma. Efficacy and toxicity in a real-world setting may differ from clinical trials, due to more liberal eligibility criteria and less intensive monitoring. Moreover, high cost
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b3a5935e1dff75fd9a40239be22a5eb
https://hdl.handle.net/11250/2989543
https://hdl.handle.net/11250/2989543
Autor:
Ji-Eun Lee, Se Young Kim, Jae-Ho Yoo, Il Tae Hwang, Jung Sub Lim, Kyung Hee Yi, Young-Jun Rhie, Gyung Min Lee, Hyo-Kyoung Nam, Hyun Wook Chae, Eun Young Kim, Chong Kun Cheon, Jieun Lee, Young Suk Shim, YuJin Lee, Jin Soon Hwang
Publikováno v:
Patient preference and adherence
Ji-Eun Lee,1 Se Young Kim,2 Jae-Ho Yoo,3 Il Tae Hwang,4 Jung Sub Lim,5 Kyung Hee Yi,6 Young-Jun Rhie,7 Gyung Min Lee,8 Hyo-Kyoung Nam,9 Hyun Wook Chae,10 Eun Young Kim,11 Chong Kun Cheon,12 Jieun Lee,13 Young Suk Shim,14 YuJin Lee,15 Eun Young Kim,15
Autor:
Tamara Brkic, Benjamin Lawrence Wilkes, Rhiannon Fogliati, Richa Gupta, Blake F. Dear, Steve Bailey, Ashwin Singh, Milena Gandy, Bareena Johnson, Joanne Dudeney, Michael P. Jones, Nickolai Titov
Publikováno v:
Journal of Affective Disorders. 256:567-577
Background There has been growing interest in the potential of emerging internet-delivered psychological treatments for supporting the mental health needs of university students. However, no large-scale prospective effectiveness trials examining thei